LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Open

SectorHealthcare

212.2 0.94

Buy Sell

Overview

Share price change

24h

Current

Min

208.24

Max

214.19

Key metrics
By Trading Economics
Income	-22M -61M
Sales	56M 214M
Profit margin	-28.549
Employees	1,017
EBITDA	-56M -53M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+25.68% upside

Market Stats
By TradingEconomics
Market Cap	902M 13B
Previous open	211.26
Previous close	212.2

News Sentiment

By Acuity

50%

168 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lis 2025, 16:49 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 lis 2025, 15:32 UTC

Acquisitions, Mergers, Takeovers

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 lis 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 lis 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 lis 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 lis 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 lis 2025, 15:54 UTC

Acquisitions, Mergers, Takeovers

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 lis 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 lis 2025, 15:43 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 lis 2025, 15:42 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 lis 2025, 15:41 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 lis 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 lis 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 lis 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 lis 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 lis 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 lis 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 lis 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27 lis 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 lis 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27 lis 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27 lis 2025, 11:07 UTC

Earnings

Genting: Positive About Prospects Over Longer Term

27 lis 2025, 11:06 UTC

Earnings

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 lis 2025, 11:04 UTC

Earnings

Genting: International Travel Demand Expected to Remain Resilient

27 lis 2025, 11:04 UTC

Earnings

Genting: Global Growth Expected to Remain Subdued

27 lis 2025, 11:04 UTC

Earnings

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 lis 2025, 10:59 UTC

Earnings

Genting Bhd 3Q Net Profit Fell 86% on Year

27 lis 2025, 10:58 UTC

Earnings

Genting Bhd 3Q Rev Rose 14% on Year

27 lis 2025, 10:56 UTC

Earnings

Genting Bhd 3Q Net MYR30.3M

27 lis 2025, 10:56 UTC

Earnings

Genting Bhd 3Q EPS MYR0.0079

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

25.68% upside

12 Months Forecast

Average 259.71 USD 25.68%

High 325 USD

Low 220 USD

Based on 15 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

168 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.